1. Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma.
- Author
-
Zhao X, Puszyk WM, Lu Z, Ostrov DA, George TJ, Robertson KD, and Liu C
- Subjects
- Animals, Antibodies, Monoclonal administration & dosage, Antineoplastic Agents pharmacology, Apoptosis, Cell Line, Tumor, Cell Proliferation drug effects, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Drug Synergism, Gene Expression Regulation, Neoplastic drug effects, Humans, Imidazoles pharmacology, Inhibitor of Apoptosis Proteins genetics, Inhibitor of Apoptosis Proteins metabolism, Mice, Mice, SCID, Naphthoquinones pharmacology, Pancreatic Neoplasms genetics, Survivin, Xenograft Model Antitumor Assays, Gemcitabine, Antineoplastic Agents administration & dosage, Imidazoles administration & dosage, Naphthoquinones administration & dosage, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms metabolism, Receptors, TNF-Related Apoptosis-Inducing Ligand metabolism
- Abstract
Despite much effort, pancreatic cancer survival rates are still dismally low. Novel therapeutics may hold the key to improving survival. YM155 is a small molecule inhibitor that has shown antitumor activity in a number of cancers by reducing the expression of survivin. The aim of our study is to understand the mechanisms by which YM155 functions in pancreatic cancer cells. We established the antitumor effect of YM155 with in vitro studies in cultured cells, and in vivo studies using a mouse xenograft model. Our data demonstrated that YM155 reduced the expression of survivin; however, downregulation of survivin itself is insufficient to induce apoptosis in pancreatic cancer cells. We showed for the first time that treatment with YM155 increased death receptor 5 (DR5) expression in pancreatic cancer cells. We found that YM155 induced apoptosis by broad-spectrum inhibition of IAP family member proteins (e.g., CIAP1/2 and FLIP) and induced proapoptotic Bak protein upregulation and activation; the antitumor effect of YM155 treatment with either the DR5 agonist lexatumumab or gemcitabine on pancreatic cancer cells was synergistic. Our data also revealed that YM155 inhibits tumor growth in vivo, without apparent toxicity to the noncancerous human pancreatic ductal epithelial cell line. Together, these findings suggest that YM155 could be a novel therapeutic agent for pancreatic cancer., (©2014 American Association for Cancer Research.)
- Published
- 2015
- Full Text
- View/download PDF